Hepatitis B: Reflections on the current approach to antiviral therapy
Open Access
- 13 February 2008
- journal article
- review article
- Published by Elsevier
- Vol. 48, S2-S19
- https://doi.org/10.1016/j.jhep.2008.01.011
Abstract
No abstract availableKeywords
This publication has 126 references indexed in Scilit:
- The HBV Drug Entecavir — Effects on HIV-1 Replication and ResistanceNew England Journal of Medicine, 2007
- 508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvementJournal of Hepatology, 2006
- A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudineJournal of Viral Hepatitis, 2006
- Long‐term follow‐up of peginterferon and lamivudine combination treatment in HBeAg‐positive chronic hepatitis B†Hepatology, 2005
- 523 Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (PEGASYS®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)Journal of Hepatology, 2005
- 510 HBsAg levels under interferon and lamivudine therapy in HBeAg-negative chronic hepatitis B (CHBe-) patientsJournal of Hepatology, 2005
- 495 Viral load is a strong predictor of hepatocellular carcinoma risk in people chronically infected with hepatitis B virus and with normal serum alanine aminotransaminase levelJournal of Hepatology, 2005
- 477 Viral load as a predictor of mortality from hepatocellular carcinoma and chronic liver disease in chronic hepatitis B infectionJournal of Hepatology, 2005
- Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failureJournal of Hepatology, 2005
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004